Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Bluerock Homes Trust completed the disposition of 31 single-family residential units within its ILE portfolio between January 1 and October 14, 2026. The units were sold to unaffiliated third parties for an aggregate sales price of approximately $6.6 million, resulting in net proceeds of approximately $2.0 million after debt paydown.
First Tracks Biotherapeutics, Inc. closed a private placement of 6,106,870 shares of common stock on October 19, 2026. In connection with the closing, the company entered into a registration rights agreement requiring it to file a resale registration statement for the investors within 30 days.
Marwynn Holdings M&A Deal with Zhituo Software Co., Limited
Marwynn Holdings acquired the proprietary Phase 1 core platform of the Marwynn Group Operating Platform from Zhituo Software Co., Limited. As consideration, the company agreed to issue 4,000,000 shares of common stock, which will serve as the permanent core architecture for managing the company and its subsidiaries. The agreement includes the transfer of all worldwide intellectual property rights, source code, and technical documentation.
North Haven Net REIT sold an aggregate of 442,000 shares across multiple classes (Class I, F-I, E, and L-I) for total consideration of approximately $9.25 million. The shares were sold to a feeder vehicle and other investors based on the company's net asset value per share as of September 30, 2026.
Pluri Inc. entered into a Securities Purchase Agreement with its largest shareholder, Chutzpah Holdings LP, to issue 833,334 common shares and warrants to purchase an additional 833,334 shares. The $1.25 million aggregate purchase price was satisfied by an advance payment previously received by the company in June 2026. The shares were priced at $1.50 per share, with the warrants carrying an exercise price of $1.65.
Dorchester Minerals M&A Deal with Hillside Exploration Assets, LLC
Dorchester Minerals, L.P. entered into a definitive agreement to acquire approximately 4,300 net royalty acres in the Williston Basin from Hillside Exploration Assets, LLC. The acquisition is structured as a contribution and exchange where the seller will receive 1,250,000 common units of DMLP. The deal is expected to close on October 30, 2026, and includes a cash adjustment for receipts attributed to the properties since July 1, 2026.
Hines Private Wealth Solutions completed its largest Delaware Statutory Trust (DST) offering, HREX 9 DST, raising approximately $591 million from qualified investors. The offering consists of interests in two multifamily properties, Gables Station in Florida and Left Bank in Illinois, which were sourced from Hines Global Income Trust, Inc.
ClimateRock and GreenRock Corp have amended their definitive merger agreement to extend the deal's outside closing date from May 2, 2025, to March 31, 2027. The amendment also removes the acquisition of TEP Renewables Limited as a closing condition and eliminates the earnout escrow provision.
DataMeds AI, Inc. received formal notification from Nasdaq on October 19, 2026, confirming that the company has regained compliance with the $2.5 million minimum stockholders' equity requirement for continued listing. The company had previously been in deficiency since April 2026 and had also recently regained compliance with the minimum bid-price requirement in June 2026.
Salesforce has entered into a definitive agreement to acquire customer engagement platform Braze for approximately $5.66 billion in enterprise value. Braze shareholders will receive $47.50 per share in cash, and the acquisition is intended to strengthen Salesforce Marketing Cloud's real-time B2C engagement and AI decisioning capabilities.
Value
$5.66B
Counterparty
Braze, Inc.
“Every interaction is an opportunity to wow your customers. Most of that wow comes from knowing your customer, and responding at just the right moment. Braze was built to turn live customer behavior into personalized engagement at scale. Bringing that capability together with Salesforce Marketing Cloud, CRM, and Data 360 will deliver that wow moment in every customer interaction.”
Patrick Stokes, President, Applications and Marketing, Salesforce
“Braze was built on the conviction that marketers and their creativity are a brand’s ultimate competitive advantage. This past year we shipped at the fastest pace in our history, and BrazeAI is helping marketers get their best ideas live faster. Salesforce shares our commitment to marketers, and we’ll continue building as Braze and investing in the Braze community of customers and partners who built this company with us.”
Braze, Inc. has entered into a definitive agreement to be acquired by Salesforce, Inc. for $47.50 per share in cash. Upon completion of the merger, Braze will become a wholly owned subsidiary of Salesforce and its Class A common stock will be delisted from the Nasdaq Stock Market.
Strive, Inc. closed an upsized initial public offering of 7,000,000 shares of its 15.00% Series A Perpetual SATS Preferred Stock at a price of $90 per share, generating $630 million in gross proceeds. The new security is expected to trade on the Nasdaq Global Market under the ticker symbol 'SATS' and features a 15% annual dividend on a $100 stated amount.
Value
$630M
Term
perpetual
“The successful, upsized IPO of SATS marks a critical milestone in our strategy to maximize long-term total returns for our common equity investors. We believe maintaining a high Amplification Ratio is the most important driver of our ability to outperform Bitcoin over time. SATS provides an additional tool to achieve that objective while simultaneously strengthening SATA’s credit profile by adding junior capital beneath it.”
Matt Cole, Chairman and CEO of Strive
“SATS represents the next evolution of our commitment to developing products tailored to the distinct needs of investors, introducing a fixed-rate perpetual security to our offerings. By expanding our range of highly liquid securities, we are more precisely aligning each product with the objectives of the investors it serves.”
Dime Commercial Bancshares Signs $58M M&A Deal with ES Bancshares, Inc.
Dime Commercial Bancshares has agreed to acquire ES Bancshares, Inc. in a cash and stock transaction valued at approximately $58 million. ES Bancshares shareholders will receive a combination of $30 million in aggregate cash and 720,000 shares of Dime common stock, representing a value of $8.39 per share based on recent trading prices. Following the merger, Empire State Bank will be merged into Dime Commercial Bank.
Nu-Med Plus, Inc. entered into subscription agreements with two accredited investors for the private placement of 171,232 shares of Series A Preferred Stock, raising $450,000. The company also issued 50,000 shares of Series A Preferred Stock to a consultant as compensation for services rendered.
Beazer Homes USA M&A Deal with Dream Finders Homes, Inc.
Beazer Homes USA, Inc. completed its merger with a subsidiary of Dream Finders Homes, Inc., with Beazer surviving as a wholly owned subsidiary of Dream Finders. Shareholders of Beazer are entitled to receive $33.50 in cash per share. In connection with the closing, Beazer's existing credit agreement was terminated and its $350 million 7.250% Senior Notes due 2029 were redeemed.
Freenome launched its SimpleScreen Lung test, a blood-based screening tool for adults aged 50-80 with a significant smoking history. The company also introduced a first-of-its-kind offering that allows eligible patients to be screened for both lung and colorectal cancer (CRC) through a single blood draw using two independently validated tests.
Bold Eagle Acquisition M&A Deal with REDL Intermediate Holdings, LLC
Bold Eagle Acquisition Corp. and REDLattice announced the confidential submission of a draft Form S-4 registration statement to the SEC regarding their previously announced business combination. The transaction is expected to result in REDLattice becoming a publicly traded company on Nasdaq under the ticker symbol 'REDL'.
Myriad Genetics Divestiture to Laboratory Corporation of America for $210M
Myriad Genetics has entered into a definitive agreement to sell its prenatal health testing business, including the Foresight, Prequel, and SneakPeek tests, to Labcorp for $210 million in cash. The divestiture is part of a strategic review to focus on the company's cancer care continuum and is expected to close by early 2027.
Arcus Biosciences presented new data from its ARC-20 platform study evaluating casdatifan in various treatment lines for clear cell renal cell carcinoma (ccRCC). Key results included a 50% confirmed objective response rate (cORR) for the first-line casdatifan plus zimberelimab combination and a 14.5-month median progression-free survival for the second-line combination with cabozantinib.
Kinetic Seas announced the commercial availability of three foundational AI software platforms: MaluDB, MaluOS, and MaluMail. These products provide enterprise infrastructure for building and deploying scalable agentic and generative AI applications under a dual open-source and enterprise subscription model.
Mount Logan Capital Signs $4.6M M&A Deal with Alternative Fund Advisors, LLC
Mount Logan Management, LLC, a subsidiary of Mount Logan Capital Inc., entered into a definitive agreement to acquire the management rights and related assets of the AFA Asset Based Lending Fund (AMCLX) from Alternative Fund Advisors, LLC. Mount Logan will pay up to $4.6 million in cash and deferred installments, plus 40% of management and incentive fees for five years, to succeed AFA as the fund's investment adviser.
Value
$4.6M
Counterparty
Alternative Fund Advisors, LLC
Term
5 years
“This is a significant milestone in the build-out of Mount Logan's evergreen credit platform and reflects our continued discipline in acquiring permanent and semi-permanent capital vehicles. The Fund broadens MLM's core products, extends our distribution reach in the private wealth channel, and is highly complementary to our Opportunistic Credit Interval Fund. It also provides a differentiated, institutionally managed asset-based lending strategy that leverages the credit sourcing and underwriting capabilities of the broader Mount Logan and BC Partners Credit platform.”
XWELL, Inc. received a deficiency notice from Nasdaq on October 7, 2026, because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. The company has 180 calendar days, or until April 5, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. XWELL is monitoring the situation and considering options, including a potential reverse stock split, to address the deficiency.
Launch Two Acquisition M&A Deal with NuCube Energy, Inc.
Launch Two Acquisition Corp. entered into an amendment to its existing business combination agreement with NuCube Energy, Inc., extending the deal's outside closing date to January 7, 2027. The amendment also permits NuCube to conduct interim financing through the issuance of Series A-4 Preferred Stock and increases the post-closing employee incentive plan share reserve to 12.5%.
Prudential Financial Divestiture to CNP Assurances Group for $4.03B
Prudential Financial has entered into definitive agreements to sell its equity interests in Prudential of Brazil and Prudential of Mexico to CNP Assurances for approximately $4.025 billion in cash. The transaction is part of Prudential's strategy to exit emerging markets and refocus capital on its core growth opportunities in the U.S., Japan, and select European markets.
Maximus Signs $660M M&A Deal with Agile Defense, LLC
Maximus, Inc. has entered into a definitive agreement to acquire Agile Defense, LLC for $660 million in cash, plus up to $50 million in contingent earnout payments. The acquisition aims to expand Maximus' presence in the defense and national security markets by adding specialized cybersecurity, AI, and digital transformation capabilities. The deal is expected to close in the first quarter of fiscal year 2027, subject to regulatory approvals.
Hertz Global Holdings Partnership with Cohen Private Ventures Worth $80.9M
Hertz entered into a joint venture arrangement for its Oro Mobility business, with a consortium of investors purchasing a 50% voting interest and 15.86% economic interest in the JV entity for $80.89 million. Hertz will retain majority economic ownership and serve as a fleet and corporate services partner to Oro, which operates approximately 45,000 vehicles across U.S. mobility markets. Concurrently, Hertz repurchased $51.1 million of its 2029 exchangeable notes from the investors at a 60% discount to par.
Value
$80.9M
Counterparty
Cohen Private Ventures, Certares Opportunities LLC, and Knighthead Capital Management, LLC
Iridium Communications M&A Deal with Rocket Lab Corporation
Iridium provided a status update on its pending acquisition by Rocket Lab, noting that stockholders approved the transaction on September 24, 2026, with 99.6% of votes cast in favor. The deal is expected to close by mid-2027, following the company's recent completion of its acquisition of Aireon.
Counterparty
Rocket Lab Corporation
“Last month’s stockholder approval for Rocket Lab’s acquisition of Iridium was an important milestone in creating a next generation space powerhouse.”
Matt Desch, CEO, Iridium
“The combination of these two leading space companies will unlock new innovation in the space industry and accelerate our growth in critical space-based missions.”
Odyssey Therapeutics announced positive Phase 2a results for its oral RIPK2 inhibitor, OD-001, in patients with moderate-to-severe ulcerative colitis. The trial met its primary endpoint with a 27% clinical remission rate at the 20 mg BID dose at Week 12, showing significant correlation between clinical efficacy and inflammatory biomarkers.
Quoin Pharmaceuticals announced the publication of a peer-reviewed case report detailing 21 months of compassionate use treatment with QRX003 in a pediatric Netherton Syndrome patient, showing an improvement from severe to clear skin. The company also reaffirmed that its ongoing Phase 2/3 study of QRX003 expects to complete recruitment by the end of 2026 with topline data anticipated in Q2 2027.
Rapport Therapeutics announced positive topline results from its Phase 2 trial of RAP-219 for the treatment of bipolar mania, meeting the primary endpoint with a statistically significant 3.1-point placebo-adjusted improvement in the YMRS total score. The drug was well-tolerated with no serious adverse events, establishing clinical proof-of-concept for its novel TARP g8-selective mechanism. The company plans to progress RAP-219 into Phase 3 trials for bipolar mania in the second half of 2027.